Dupilumab and the potential risk of eosinophilic pneumonia: case report, literature review, and FAERS database analysis

Dupilumab and the potential risk of eosinophilic pneumonia: case report, literature review, and FAERS database analysis

Eosinophilic pneumonia (EP) is a rare but noteworthy adverse effect linked to dupilumab, an interleukin-4 (IL-4) and IL-13 inhibitor used in the managing atopic diseases. The underlying mechanisms, potential predisposing factors, clinical characteristics, and optimal management strategies for dupilu...

Full description

Bibliographic Details
Main Authors: Xiyuan Zhou, Ge Yang, Xuemei Zeng, Lan Wang, Jing Xiang, Jinyu Zhao, Xuejun Chen, Lixia Zhang
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-01-01
Series:Frontiers in Immunology
Subjects:
dupilumab
eosinophilic pneumonia
risk analysis
case report
FAERS database
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1277734/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1277734/full

Similar Items